Skip to content

Study · Randomized controlled trial · n = 24 · 2023

5 results

Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial.

Nielsen CK, Øhrstrøm CC, Houji IJK, Helsted MM, Krogh LSL, Johansen NJ, Hartmann B, Holst JJ, Vilsbøll T, Knop FK

Diabetes care1 Dec 2023Cited by 14 (Europe PMC)

PMID37819999 (opens in a new tab)DOI10.2337/dc23-1193 (opens in a new tab)PepBankPUB-37819999
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After gastric bypass, dasiglucagon reduced time in level 1 hypoglycemia by 33% versus placebo, a -1.2 percentage point difference, P = 0.002.

    In plain wordsAfter gastric bypass, dasiglucagon reduced time in level 1 hypoglycemia by 33% compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime in level 1 hypoglycemia
    Study

    n = 24

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 μg · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Relative reduction
    33%
    level 1 hypoglycemia
    Difference
    −1.2 percentage points
    versus placebo
    95% CI
    −2 to −0.5 percentage points
    difference

    Source sentences

    Summary
    Compared with placebo, treatment with dasiglucagon significantly reduced time in level 1 hypoglycemia by 33% (-1.2 percentage points; 95% CI -2.0 to -0.5; P = 0.002) and time in level 2 hypoglycemia by 54% (-0.4 percentage points; 95% CI -0.6 to -0.2; P < 0.0001).
    4 context sentences
    Summary · context
    The primary and key secondary outcomes were continuous glucose monitor-captured percentage of time in level 1 and 2 hypoglycemia (<3.9 and <3.0 mmol/L), respectively.
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.
    Summary · context
    The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women)
    Summary · context
    randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    After gastric bypass, dasiglucagon reduced time in level 2 hypoglycemia by 54% versus placebo, a -0.4 percentage point difference, P < 0.0001.

    In plain wordsAfter gastric bypass, dasiglucagon reduced time in level 2 hypoglycemia by 54% compared with placebo.

    Peptide
    Dasiglucagon
    Outcome
    DecreaseTime in level 2 hypoglycemia
    Study

    n = 24

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 μg · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Relative reduction
    54%
    level 2 hypoglycemia
    Difference
    −0.4 percentage points
    versus placebo
    95% CI
    −0.6 to −0.2 percentage points
    difference

    Source sentences

    Summary
    Compared with placebo, treatment with dasiglucagon significantly reduced time in level 1 hypoglycemia by 33% (-1.2 percentage points; 95% CI -2.0 to -0.5; P = 0.002) and time in level 2 hypoglycemia by 54% (-0.4 percentage points; 95% CI -0.6 to -0.2; P < 0.0001).
    4 context sentences
    Summary · context
    The primary and key secondary outcomes were continuous glucose monitor-captured percentage of time in level 1 and 2 hypoglycemia (<3.9 and <3.0 mmol/L), respectively.
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.
    Summary · context
    The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women)
    Summary · context
    randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    After gastric bypass, dasiglucagon corrected hypoglycemia within 15 min in 401 of 412 administrations versus 104 of 357 with placebo, P < 0.001.

    In plain wordsAfter gastric bypass, dasiglucagon corrected hypoglycemia within 15 minutes in 97.3% of administrations versus 29.1% with placebo.

    Peptide
    Dasiglucagon
    Outcome
    IncreaseHypoglycemia correction within 15 minutes
    Study

    n = 24

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    120 μg · subcutaneous · 4 weeksAs given in this study (human).

    Measurements

    Correction rate
    97.3%
    dasiglucagon
    Correction rate
    29.1%
    placebo
    Corrections within 15 min
    401 self-administrations
    dasiglucagon
    Self-administrations
    412 self-administrations
    dasiglucagon
    Corrections within 15 min
    104 self-administrations
    placebo
    Self-administrations
    357 self-administrations
    placebo

    Source sentences

    Summary
    Furthermore, dasiglucagon corrected hypoglycemia within 15 min in 401 of 412 self-administrations, compared with 104 of 357 placebo self-administrations (97.3% vs. 29.1% correction of hypoglycemia rate; P < 0.001).
    3 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.
    Summary · context
    The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women)
    Summary · context
    randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo.
  4. 04HumanNon-randomized trialSafety outcome

    In individuals after gastric bypass, dasiglucagon was generally well tolerated.

    In plain wordsIn individuals after gastric bypass, dasiglucagon was generally well tolerated.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableOverall tolerability
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    120 μg · subcutaneous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea.
    3 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.
    Summary · context
    The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women)
    Summary · context
    randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo.
  5. 05HumanNon-randomized trialSafety outcome

    In individuals after gastric bypass, dasiglucagon adverse events included mostly mild to moderate nausea.

    In plain wordsIn individuals after gastric bypass, dasiglucagon adverse events included mostly mild to moderate nausea.

    Peptide
    Dasiglucagon
    Outcome
    Not applicableNausea
    Study

    n = 24

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    120 μg · subcutaneous · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Dasiglucagon was generally well tolerated, with mostly mild to moderate adverse events of nausea.
    3 context sentences
    Summary · context
    We conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.
    Summary · context
    The study included 24 individuals who had undergone Roux-en-Y gastric bypass surgery (n = 23 women)
    Summary · context
    randomly assigned to two treatment periods of 4 weeks of self-administered subcutaneous dasiglucagon at 120 μg or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.